<?xml version="1.0" ?>
<document id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f">
  <chunk id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c0" text="Etanercept for steroid-refractory acute graft- versus-host disease: A single center experience">
    <entity charOffset="0-10" id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c0.e0" ontology_id="CHEBI_4875" text="Etanercept" type="chemical"/>
  </chunk>
  <chunk id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c1" text="Acute graft-versus-host disease (aGVHD) is an important complication of allogeneic stem cell transplantation (alloSCT). High dose glucocorticosteroids, are currently recommended as first-line treatment for grade II-IV aGVHD resulting in overall complete responses (CR) in 40%-50% of patients. No standard second-line regimen has been established. Different options have been reported, including anti-TNFÎ± antibodies.">
    <entity charOffset="24-31" id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c1.e0" ontology_id="DOID_4" text="disease" type="disease"/>
  </chunk>
  <chunk id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c2" text="We retrospectively reviewed the outcome of 15 patients with steroid-refractory (SR) aGVHD treated with etanercept at our institution. Patients were transplanted for a hematological malignancy and received either a myeloablative or a non-myeloablative conditioning regimen. Prophylaxis of GVHD consisted of cyclosporin A and mycophenolic acid.">
    <entity charOffset="103-113" id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c2.e0" ontology_id="CHEBI_4875" text="etanercept" type="chemical"/>
    <entity charOffset="306-319" id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c2.e1" ontology_id="CHEBI_4031" text="cyclosporin A" type="chemical"/>
  </chunk>
  <chunk id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c3" text="Acute GVHD was diagnosed at a median of 61 days post-transplantation. All patients had grade III aGVHD of the gut. Second-line treatment with etanercept was started at a median of 13 days after initiation of first-line therapy. Overall response rate was 53%, with CR in 3 patients and PR in 5 patients. Median overall survival after initiation of treatment with etanercept was 66 days (range 5-267) for the entire group. Median overall survival was 99 days (range 47-267 days) for responders and 17 days (range 5-66 days) for non-responders (p&lt;0.01). Nevertheless, all patients died. Causes of death were progressive GVHD in 7 patients (47%), infection in 6 patients (40%), cardiac death in 1 patient (6.7%) and relapse in 1 patient (6,7%).">
    <entity charOffset="142-152" id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c3.e0" ontology_id="CHEBI_4875" text="etanercept" type="chemical"/>
    <entity charOffset="362-372" id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c3.e1" ontology_id="CHEBI_4875" text="etanercept" type="chemical"/>
  </chunk>
  <chunk id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c4" text="Second-line treatment with etanercept does induce responses in SR-aGVHD of the gut but appears to be associated with poor long-term survival even in responding patients.">
    <entity charOffset="27-37" id="6fd5ec9e4ec79f24c0bf011e388410d8ec35fe0f.c4.e0" ontology_id="CHEBI_4875" text="etanercept" type="chemical"/>
  </chunk>
</document>
